Yangzijiang return to home base region

Base formation or support zone breakdown?

Monitor support zone.

Jiutian Strong Buying

Strong buying by BB.

They must know something we do not know.

RNAi Gene Silencing Applications Advance

Researchers from academia and industry will present the latest developments in the application of interference RNA (RNAi) as a tool for gene silencing at “RNAi2008 Functions and Applications of Non-coding RNAs” to be held in March in Oxford, U.K. The meeting will focus on advances in the field and current opportunities and challenges in developing RNAi-based strategies for use in understanding the molecular mechanisms underlying disease processes, identifying new drug targets, and developing therapeutic agents capable of silencing disease-related genes.

siRNA Therapeutics

“Refined Animal Models for Optimizing Delivery of Functional siRNAs to Skin,” is the title of the presentation to be given by Roger Kaspar, Ph.D., on behalf of TransDerm (www.transderm.org). The skin disorder on which the company is focusing its initial product development effort is pachyonychia congenital (PC), a rare autosomal dominant disease in which a mutation in the gene for keratin 6a (K6a) causes painful skin lesions to form. The K6a N171 mutation is a single-nucleotide replacement mutation in which an adenine is present in the mutant gene form in place of a cytosine, resulting in an amino acid change.

Dr. Kaspar, CEO of TransDerm, will describe how the company’s TD101 therapeutic small interfering RNA (siRNA) specifically targets the N171K mutant form of the gene without affecting the wild-type gene.

To assess the activity of TD101 and optimize a controlled-dose delivery system, TranDerm is developing transgenic mouse models. In collaboration with Christopher Contag, Ph.D., and colleagues in the molecular imaging program at Stanford University, the company is using molecular imaging in transgenic mice to demonstrate the effectiveness of siRNA knockdown of reporter genes.

Two in vivo imaging-based approaches for validating RNAi activity have yielded quantitative and qualitative evidence of gene expression inhibition. In one method, the researchers intradermally coinjected a plasmid expressing the firefly reporter gene luciferase with siRNA molecules targeting the reporter gene mRNA into mouse paws. The results demonstrated potent inhibition of luciferase expression. Northern blot analysis supported luciferase mRNA inhibition as the mechanism of action.

The second method involved the construction of a mutant K6a/luciferase bicistronic reporter construct that was codelivered into mouse skin with K6a mutant-specific siRNAs. In vivo bioluminescence-based imaging showed weak luciferase activity in the coinjected mouse skin compared to control animals.

The company plans to use human skin explants derived from PC patient biopsies grafted onto immunocompromised, nude mice as a test stage to determine whether the RNAi activity seen in mouse skin will translate to similar efficacy in human skin samples. This work, being carried out with collaborators at the Ciemat Institute in Madrid, Spain, is still in the early stages.

TransDerm’s TD101 product is an unmodified siRNA intended to be administered directly to the PC lesions. Although intradermal injection offers a reliable delivery method, it is not a particularly patient-friendly option, especially given the need for repeated administration of the drug to treat new lesions. TransDerm is experimenting with two alternative siRNA delivery methods.

One is a topical, lipid-based formulation called GeneCreme. Its main limitation at present is how to ensure reliable uptake and dosing. The other approach is called the Soluble Tip Microneedle Array. Each array is composed of a grid of dissolvable, hollow protrusions into which siRNAs can be loaded. The microneedles penetrate the outer layer of the skin, the stratum corneum, where the tips are dislodged and remain. Time-release dispersion of the siRNA occurs as the tips dissolve.

“An ideal application would be to embed the array in a type of Band-aid device that the patient would apply and push down on to deliver the drug,” says Dr. Kaspar.

siRNA drugs intended for systemic administration require chemical modification or some sort of protective packaging to prevent rapid enzymatic degradation in the bloodstream, which would compromise their ability to reach the intended target and to exert a therapeutic effect.

Jørgen Kjems, Ph.D., a professor in the department of molecular biology at Aarhus University in Denmark, part of the Interdisciplinary Nanoscience Center (iNANO; www.inano.dk), is experimenting with three-stranded siRNAs as a means of optimizing the ability to introduce chemical modifications without changing the molecules’ activity.

Dr. Kjems begins with a small, double-stranded RNA, keeps one strand whole, and cleaves the second nonfunctional strand into two pieces. The result is a short internally segmented interfering RNA (sisiRNA). His group has demonstrated that these three-stranded constructs are amenable to a greater number of chemical modifications. With a double-stranded RNAi molecule about 20% of the nucleotides can be modified without losing activity, 100% of the nucleotides in an sisiRNA molecule can undergo chemical modification, allowing for more options to improve their pharmacodynamic properties.

This finding created an opportunity for evaluating a large variety of chemical modifications. Dr. Kjems has shown that the difference between an unmodified siRNA and a fully modified sisiRNA may be as great as a 100-fold increase in stability in serum.

This triple-stranded approach offers an additional benefit related to RNAi uptake and activity. When an siRNA is taken up by a cell, an intracellular complex selects one of the two RNA strands to retain. With the sisiRNA, the uncleaved strand—the active strand—is preferentially retained.

http://www.genengnews.com/articles/chitem.aspx?aid=2343

Cornell receives almost $2 million from New York state for stem cell research

Cornell University received two one-year institutional development grants for stem cell research from the state of New York as part of $14.5 million in similar awards granted statewide Jan. 7. A grant to Cornell's Ithaca campus totaled $1 million, while a second award for $997,382 was given to the Weill Cornell Medical College in New York City. These are the first grant awards from New York's new $600 million, multiyear stem cell research program that came out of a stem cell research initiative in the 2007-08 state budget.

"This is a major boost for our stem cell programs and will support individual projects, core facilities and collaborative stem cell research on campus," said Michael Kotlikoff, the Austin O. Hooey Dean of Cornell's College of Veterinary Medicine. "The program brings investigators together from several colleges and includes work on stem cell biology and cancer, as well as translational projects using human embryonic stem cell lines in animal models of human disease."

Cornell currently has investigators who conduct research on embryonic and adult stem cells, basic stem cell biology and the use of stem cells to treat cancer, cardiovascular and degenerative disorders. Also, compared to other institutions, Cornell researchers engage in "unparalleled interdisciplinary interactions," and the veterinary college gives Cornell the unique advantage of comparing stem cells across species, as researchers here study mouse, dog, horse and human stem cells, said Alexander Nikitin, the principal investigator of the grant and associate professor of pathology in the Department of Biomedical Sciences at the veterinary college.

He said investigators on the Ithaca campus from the Departments of Molecular Biology and Genetics and of Biomedical Engineering will receive the funding. The money will be divided approximately 50 percent for research, 20 percent for training new investigators in stem cell science and 30 percent for acquiring new instruments for conducting research. Some funds also will go toward establishing a Cornell stem cell program that will offer workshops and will invite national and international experts to Cornell to give seminars and training, Alexander Nikitin, the principal investigator of the grant and associate professor of pathology in the Department of Biomedical Sciences at the veterinary college, Nikitin said.

At the Weill Cornell Medical College's Ansary Stem Cell Center for Regenerative Medicine, the state grant will provide scientists and students the funds to examine the prospective uses of both adult stem cells and embryonic stem cells.

http://www.bionity.com/news/e/76725/

Investors continue to funnel money into biotechnology

Science and Patents

Investors continue to funnel money into biotechnology because it has innovative science and long-term patents that large drugmakers need, Neff said on a Jan. 18 conference call with reporters. Pharmaceutical companies have cash, development and marketing expertise that the smaller companies don't, making them natural partners and acquirers, he said.

``We've been saying it for a while, but now it's playing out in dramatic ways,'' said Ashley Dombkowski, a general partner with MPM Capital in South San Francisco, California, in a telephone interview. MPM has $2.5 billion under management in biotechnology and medical device companies.

Pfizer, for instance, said on Dec. 18 it will buy closely held CovX for an undisclosed amount to acquire experimental drugs for cancer and diabetes. CovX, a La Jolla, California- based biotechnology company, has one diabetes drug and two cancer drugs in early stages of development, Pfizer said.

Acquisitions

The acquisition of Pharmion Corp. by Celgene Corp. of Summit, New Jersey, for $2.9 billion and Tokyo-based Eisai Co.'s $3.9 billion purchase of MGI Pharma Inc. are other examples of the desire for large drugmakers to acquire smaller innovators, Dombkowski said.

Still, there are reasons for concern among biotechnology and medical device investors, Neff said. The budget of the U.S. National Institutes of Health, which produces many basic discoveries for biotechnology companies to develop further, is under pressure, Neff said.

Patent law changes could undermine biotechnology companies, and legislative efforts to control high drug prices could also harm the industry, he said.

Not all types of biotechnology companies are flush with cash, Neff said. Cancer drug developers are having a hard time raising new venture capital. So many companies are pursuing the same opportunities that it's becoming difficult to enroll patients in new clinical trials, he said.

http://www.bloomberg.com/apps/news?pid=newsarchive&sid=aPfPR4XSrg1k

Jade Volume Distribution Chart

Only Retailers in this counter.

Why is BB missing ?

Trade with EXTREME CAUTION.